Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
NA
70 participants
INTERVENTIONAL
2025-10-31
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Parents' HPV Stories
NCT06704308
Hashtag HPV: HPV Vaccine Twitter Education Program
NCT05204030
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
NCT00798265
An Evaluation of Tailored Messages to Address Parental Questions About HPV Vaccination
NCT03628885
Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness
NCT05006833
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tailored Messaging
Tailored messages based on parents' HPV vaccine hesitancy and perceived barriers to vaccination.
Tailored messages
Messages will be individually tailored to parents' responses to a baseline survey (child gender, vaccination status) and real-time responses to interactive prompts about vaccine hesitancy determinants with links to additional information (e.g., CDC, NJ Department of Health) and community resources to overcome barriers.
Standard Messaging
Standard (untailored) messages about HPV vaccination reminder/recall.
Standard messages
Generic reminder/recall HPV vaccination messages.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tailored messages
Messages will be individually tailored to parents' responses to a baseline survey (child gender, vaccination status) and real-time responses to interactive prompts about vaccine hesitancy determinants with links to additional information (e.g., CDC, NJ Department of Health) and community resources to overcome barriers.
Standard messages
Generic reminder/recall HPV vaccination messages.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* identify as Black or African American adult;
* have access to personal mobile phone and agree to send/receive MMS messages;
* able to speak and understand English; and
* able to provide informed consent to participate
Exclusion Criteria
* does not identify as Black or African American adult;
* does not have personal mobile phone;
* unable to speak and understand English;
* not willing to consent to participate
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Rutgers, The State University of New Jersey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Racquel Kohler, PhD, MSPH
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Racquel Kohler, PhD
Role: PRINCIPAL_INVESTIGATOR
Rutgers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rutgers
New Brunswick, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
132211
Identifier Type: OTHER
Identifier Source: secondary_id
Pro2022001385
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.